Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 446 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyotrophic Lateral Sclerosis (ALS) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 21, 2026, 11:12 AM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

NCT04514952
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Not applicable Interventional

Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS

NCT03202017
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Expiratory Muscle Strength Training (EMST), EMST + Lung Volume Recruitment (LVR)
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Regimen I NUZ-001

NCT07410806
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NUZ-001, Matching placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcome Assessment for AT & BCI

NCT07407725
View directory record Official record
Conditions
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Eye Tracker, Mouth Operated Joystick, Non-invasive electroencephalogram (EEG) Headset, Implantable Brain-Computer-Interface, Personal Assistive Technology, Voice Control
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

NCT00244244
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
arimoclomol
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Irvine, California • Miami, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Results available

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 21, 2026, 11:12 AM EDT
Terminated Phase 3 Interventional

Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)

NCT01016522
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Jul 21, 2026, 11:12 AM EDT
Not yet recruiting Not applicable Interventional

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

NCT07454733
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Video recording, Notes Instruction
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1 Interventional

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

NCT01091142
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
San Francisco, California • Kansas City, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Jul 21, 2026, 11:12 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

NCT03338114
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT (orally disintigrating tablet)
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting Not applicable Interventional

Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study

NCT06119087
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Chronic Respiratory Failure, Airway Clearance Impairment, Neuromuscular Diseases
Interventions
Mechanical insufflation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)

NCT02714036
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ibudilast
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Patchogue, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease

NCT03645031
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Neuromuscular Diseases
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Phase 2 Interventional

Tofersen in Non-SOD1 ALS

NCT07294144
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Tofersen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)

NCT00919555
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pioglitazone and Tretinoin, Tretinoin and Pioglitazone HCL, Placebo
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Jul 21, 2026, 11:12 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jul 21, 2026, 11:12 AM EDT
Recruiting Not applicable Interventional

Spinal Cord Associative Plasticity for ALS

NCT06172621
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spinal Cord Associative Plasticity (SCAP), Upper extremity task-oriented exercise
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 11:12 AM EDT